期刊
CANCER CELL
卷 27, 期 4, 页码 473-488出版社
CELL PRESS
DOI: 10.1016/j.ccell.2015.03.005
关键词
-
资金
- Leukaemia and Lymphoma Research [08014, 08048, 09009, 12009]
- CRUK [C1477/A10834, C34999/A18087]
- BioInvent
- Cancer Research UK
- Millennium Takeda
- Pfizer
- Medical Research Council [1254288] Funding Source: researchfish
Therapeutic antibodies have transformed cancer therapy, unlocking mechanisms of action by engaging the immune system. Unfortunately, cures rarely occur and patients display intrinsic or acquired resistance. Here, we demonstrate the therapeutic potential of targeting human (h) Fc gamma RIIB (CD32B), a receptor implicated in immune cell desensitization and tumor cell resistance. Fc gamma RIIB-blocking antibodies prevented internalization of the CD20-specific antibody rituximab, thereby maximizing cell surface accessibility and immune effector cell mediated antitumor activity. In hFc gamma RIIB-transgenic (Tg) mice, Fc gamma RIIB-blocking antibodies effectively deleted target cells in combination with rituximab, and other therapeutic antibodies, from resistance-prone stromal compartments. Similar efficacy was seen in primary human tumor xenografts, including with cells from patients with relapsed/refractory disease. These data support the further development of hFc gamma RIIB antibodies for clinical assessment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据